Townsquare Capital LLC Buys 4,287 Shares of Illumina, Inc. (NASDAQ:ILMN)

Townsquare Capital LLC lifted its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 26.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 20,483 shares of the life sciences company's stock after buying an additional 4,287 shares during the period. Townsquare Capital LLC's holdings in Illumina were worth $1,625,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Diversified Trust Co bought a new stake in shares of Illumina in the first quarter valued at approximately $355,000. State of Alaska Department of Revenue raised its position in Illumina by 2.5% during the first quarter. State of Alaska Department of Revenue now owns 18,527 shares of the life sciences company's stock valued at $1,469,000 after purchasing an additional 445 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Illumina by 4.9% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 199,176 shares of the life sciences company's stock valued at $15,803,000 after purchasing an additional 9,252 shares in the last quarter. Merit Financial Group LLC raised its position in Illumina by 344.8% during the first quarter. Merit Financial Group LLC now owns 13,036 shares of the life sciences company's stock valued at $1,034,000 after purchasing an additional 10,105 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. raised its position in Illumina by 15.1% during the first quarter. Robeco Institutional Asset Management B.V. now owns 516,293 shares of the life sciences company's stock valued at $40,963,000 after purchasing an additional 67,676 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ILMN has been the subject of several research analyst reports. Piper Sandler lowered their price objective on shares of Illumina from $190.00 to $185.00 and set an "overweight" rating for the company in a research report on Thursday, May 15th. JPMorgan Chase & Co. lowered their price objective on shares of Illumina from $120.00 to $85.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. Evercore ISI boosted their price objective on shares of Illumina from $116.00 to $128.00 and gave the company an "outperform" rating in a research report on Tuesday, July 8th. Stephens set a $110.00 price target on shares of Illumina and gave the stock an "overweight" rating in a report on Monday, August 4th. Finally, Barclays upped their price target on shares of Illumina from $85.00 to $90.00 and gave the stock an "underweight" rating in a report on Friday, August 1st. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $124.58.

Illumina Stock Performance

Shares of ILMN opened at $101.11 on Thursday. The stock has a market capitalization of $15.54 billion, a P/E ratio of 12.80, a price-to-earnings-growth ratio of 2.19 and a beta of 1.37. The firm's fifty day simple moving average is $96.10 and its two-hundred day simple moving average is $90.64. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.17. The company had revenue of $1.06 billion for the quarter, compared to analysts' expectations of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The business's revenue was down 4.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.36 EPS. As a group, analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.